Regina G Kelmann

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Signaling Pathway

Top Venues

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Richard D Lutze, Matthew A Ingersoll, Regina G Kelmann, Tal Teitz
Trametinib, a MEK1/2 Inhibitor, Protects Mice from Cisplatin- and Noise-Induced Hearing Loss. Pharmaceuticals (Basel, Switzerland) 17 (6) (2024)
Richard D Lutze, Matthew A Ingersoll, Regina G Kelmann, Tal Teitz
Trametinib, a MEK1/2 Inhibitor, Protects Mice from Cisplatin- and Noise-Induced Hearing Loss. Pharmaceuticals (Basel, Switzerland) 17 (6) (2024)
Richard D Lutze, Matthew A Ingersoll, Regina G Kelmann, Tal Teitz
Trametinib, a MEK1/2 Inhibitor, Protects Mice from Cisplatin- and Noise-Induced Hearing Loss. Pharmaceuticals (Basel, Switzerland) 17 (6) (2024)
Richard D Lutze, Matthew A Ingersoll, Regina G Kelmann, Tal Teitz
Trametinib, a MEK1/2 Inhibitor, Protects Mice from Cisplatin- and Noise-Induced Hearing Loss. Pharmaceuticals (Basel, Switzerland) 17 (6) (2024)